The Comparative Effects of Valsartan and Amlodipine on vWf Levels and N/L Ratio in Patients with Newly Diagnosed Hypertension

REFERENCES

• Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A. High-normal blood pressure progression to hypertension in the Framingham Heart Study. Hypertension 1991; 17(1):22–27.
   PubMed Web of Science ®Google Scholar
• Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6:217–246.
   PubMedGoogle Scholar
• Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 2007; 120(Suppl.):S5–S9.
   PubMedGoogle Scholar
• Jansson JH, Nilsson TK, Johnson O. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart (British Cardiac Society) 1998; 80(4):334–337.
   PubMed Web of Science ®Google Scholar
• Harrison DG, Guzik TJ, Lob HE, . Inflammation, immunity, and hypertension. Hypertension 2011; 57(2):132–140.
   PubMed Web of Science ®Google Scholar
• Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102(1):5–14.
   PubMedGoogle Scholar
• Horne BD, Anderson JL, John JM, . Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45(10):1638–1643.
   PubMed Web of Science ®Google Scholar
• Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clinica Chimica Acta 2008; 395(1–2):27–31.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Cannon CP, Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction 18 trial) substudy. J Am Coll Cardiol 2002; 40(10):1761–1768.
   PubMedGoogle Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12):1462–1536.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 2003; 96(11):793–807.
   PubMed Web of Science ®Google Scholar
• Weir MR, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich, Conn) 2007; 9(2):103–112.
   PubMedGoogle Scholar
• Tyler HM. Amlodipine: an effective once-daily antihypertensive agent. J Hum Hypertens 1991; 5(Suppl 1):61–66.
   PubMedGoogle Scholar
• Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest 1987; 47(2):143–149.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289(19):2560–2572.
   PubMed Web of Science ®Google Scholar
• Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17(4):223–230.
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Lawlor DA, Harbord R, Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25(5):1051–1056.
   PubMed Web of Science ®Google Scholar
• Momiyama Y, Kawaguchi A, Kajiwara I, Prognostic value of plasma high-sensitivity C-reactive protein levels in Japanese patients with stable coronary artery disease: the Japan NCVC-Collaborative Inflammation Cohort (JNIC) study. Atherosclerosis 2009; 207(1):272–276.
   PubMed Web of Science ®Google Scholar
• Tsai JC, Sheu S-hsiung, Chiu H-chia, Chang D-ming. Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes Metabol Res Rev 2007( May 2006):111–118.
   Google Scholar
• Gillum RF, Mussolino ME, Madans JH. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol 2005; 15(4):266–271.
   PubMed Web of Science ®Google Scholar
• Zazula AD, Précoma-Neto D, Gomes AM, . An assessment of neutrophils/lymphocytes ratio in patients suspected of acute coronary syndrome. Arq Bras Cardiol 2008; 90(1):31–36.
   PubMed Web of Science ®Google Scholar
• Akpek M, Kaya M, Lam Y, . Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2012; 110(5):621–627.
   PubMed Web of Science ®Google Scholar
• Kalay N, Dogdu O, Koc F, Hematologic parameters and angiographic progression of coronary atherosclerosis. Angiology 2012; 63(3):213–217.
   PubMed Web of Science ®Google Scholar
• Blann A. Von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 1993; 50(2):125–134.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 1998; 18(9):1359–1362.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med 1999; 340(115):26.
   Google Scholar
• Wu C, Ye P, Li S.Circulating immune complexes correlate with collagen carboxypropeptide in patients with essential hypertension. Blood Press 2012; 21(1):19–23.
   PubMed Web of Science ®Google Scholar
• Nadar S, Blann AD, Lip GYH. Antihypertensive therapy and endothelial function. Curr Pharm Des 2004; 10(29):3607–3614.
   PubMed Web of Science ®Google Scholar
• Suleyman H, Halici Z, Hacimuftuoglu A, Gocer F. Role of adrenal gland hormones in antiinflammatory effect of calcium channel blockers. Pharmacol Rep 2006; 58(5):692–699.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Kikuchi T, Mitsuhashi T, Kimura H, Tsuchida Y, Otsuka K. Administration of angiotensin receptor II blockade improves vascular function, urinary albumin excretion, and left ventricular hypertrophy in low-risk essential hypertensive patients receiving antihypertensive treatment with calcium channel blockers. Clin Exp Hypertens 2012; [Epub ahead of print].
   Google Scholar
• Bakris GL, Williams M, Dworkin L, Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36(3):646–661.
   PubMed Web of Science ®Google Scholar
• Marfella R, Siniscalchi M, Nappo F, Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 2005; 18(3):308–318.
   PubMed Web of Science ®Google Scholar
• Moubarak M, Jabbour H, Smayra V, Cardiorenal syndrome in hypertensive rats: microalbuminuria, inflammation and ventricular hypertrophy. Physiol Res 2012; 61(1):13–24.
   PubMed Web of Science ®Google Scholar
• Remková A, Remko M. Markers of endothelial function in the early stages of essential hypertension and the effect of antihypertensive therapy. Vnitřní lékařství 2010; 56(12):1210–1216.
   PubMedGoogle Scholar
• Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37(2):440–444.
   PubMed Web of Science ®Google Scholar
• Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46(6):735–739.
   PubMed Web of Science ®Google Scholar